Lipoteichoic acid

Name: Lipoteichoic acid
Brand: MedChemExpress
SKU: HY-N9481
Rating: 4.5 (1 reviews)

Cat. No.: HY-N9481: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Lipoteichoic acid is an orally effect anti-inflammatory and antitumor agent. Lipoteichoic acid is a crucial immune molecule in Gram-positive bacteria that activates the complement system by inducing C3 and inhibiting CD55. Lipoteichoic acid regulates macrophage autophagy through the PI3K/Akt/mTOR pathway. Lipoteichoic acid induces lung damage in mice. Lipoteichoic acid inhibits the production of melanin.

For research use only. We do not sell to patients.

Lipoteichoic acid Chemical Structure

CAS No. : 56411-57-5

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All mTOR Isoform Specific Products:

View All Isoforms

mTOR mTORC1 mTORC2

View All Akt Isoform Specific Products:

View All Isoforms

Akt Akt1 Akt2 Akt3

View All PI3K Isoform Specific Products:

View All Isoforms

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All ERK Isoform Specific Products:

View All Isoforms

ERK ERK1 ERK2 ERK5 ERK8

View All Interleukin Related Isoform Specific Products:

View All Isoforms

IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Lipoteichoic acid (0.1-20 μg/mL; 12-48 h) induces macrophage autophagy by inhibiting PI3K/AKT/mTOR pathway^[2].
Lipoteichoic acid (0.1-100 μg/mL; 24 h) inhibits the production of melanin in B16F10 cells through MITF, ERK and PI3K/AKT signaling pathways^[3].
Lipoteichoic acid (50-100 ng/mL; 2-3 h) shows no cytotoxicity to HT-29 cells, decreases the secretion of TNF-α and increases the secretion of IL-10 in HT-29 cells treated with LPS (HY-D1056)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:	macrophage
Concentration:	0.1, 1, 10, and 20 μg/mL
Incubation Time:	12, 24 and 48 h
Result:	Significantly decreased the expression levels of p-Akt and p-mTOR protein, but did not affect the expression of Akt and mTOR protein.

Western Blot Analysis^[3]

Cell Line:	B16F10 cells
Concentration:	0.1, 1, 10 and 100 μg/mL
Incubation Time:	24 h
Result:	Reduced the level of MITF in a dose-dependent manner. Increased the phosphorylation levels of ERK, AKT and PI3K.

In Vivo

Lipoteichoic acid (800 μg/100 μL; Oral gavage; 7 days) shows improvement in colitis mouse model^[4].
Lipoteichoic acid (0.1 mg; Oral administration; 20 days-34 weeks) has immunomodulatory and protective effects in UV-induced tumor models^[5].
Lipoteichoic acid (5 mg/kg; Intratracheal injection; Single dose) can induce lung injury in mice^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	DSS (HY-116282C) treated male swiss albino mice aged 6-8 weeks old^[4]
Dosage:	800 μg/100 μL
Administration:	Oral gavage (i.g.); 7 days
Result:	Significantly improved external colitis symptoms, disease activity scores, and weight gain in colitis mice. Significantly improved key inflammatory markers such as the gut permeability, myeloperoxidase activity and histopathological damages in colon in colitis mice.

Animal Model:	Female Crl:SKH-1-hrBR hairless mice aged 8-12 weeks old (20-25 g) with UV-induced tumors^[5]
Dosage:	100 μL (1 mg/mL)
Administration:	Oral administration; 20 days and 34 weeks (3 times a week)
Result:	Caused T cells in the mouse inguinal lymph nodes to produce higher levels of interferon-γ and a number of total, helper and cytotoxic T cells. Significantly delayed the appearance of tumors.

Animal Model:	Male C57BL/6 mice aged 6‑8 weeks old (22±3 g)^[6]
Dosage:	5 mg/kg
Administration:	Intratracheal injection; Single dose
Result:	Induced inflammatory cell infiltration, inter‑alveolar septal thickening and alveolar collapse. Promoted the concentration of BALF total protein and the expression of inflammatory factors. Increased lung neutrophil infiltration and MPO activity.

CAS No.

56411-57-5

Appearance

Solid

Color

White to off-white

SMILES

[Lipoteichoic acid]

Structure Classification

Others

Initial Source

Microorganisms

Staphylococcus aureus

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Purity & Documentation

Select Batch:

Data Sheet (275 KB) SDS (251 KB)

COA (242 KB)

Handling Instructions (2659 KB)

References

[1]. Bong Jun Jung, et al. Lipoteichoic Acid from Staphylococcus aureus Activates the Complement System via C3 Induction and CD55 Inhibition. Microorganisms. 2021 May 24;9(6):1135. [Content Brief]

[2]. Lin D, et al. Enterococcus faecalis lipoteichoic acid regulates macrophages autophagy via PI3K/Akt/mTOR pathway. Biochem Biophys Res Commun. 2018 Apr 15;498(4):1028-1036. [Content Brief]

[3]. Kim HR, et al. Lipoteichoic acid isolated from Lactobacillus plantarum inhibits melanogenesis in B16F10 mouse melanoma cells. Mol Cells. 2015;38(2):163-70. [Content Brief]

[4]. Pradhan D, et al. Postbiotic Lipoteichoic acid of probiotic Lactobacillus origin ameliorates inflammation in HT-29 cells and colitis mice. Int J Biol Macromol. 2023 May 1;236:123962. [Content Brief]

[5]. Weill FS, et al. Lipoteichoic acid from Lactobacillus rhamnosus GG as an oral photoprotective agent against UV-induced carcinogenesis. Br J Nutr. 2013 Feb 14;109(3):457-66. [Content Brief]

[6]. Zhang Y, et al Shikonin ameliorates lipoteichoic acid induced acute lung injury via promotion of neutrophil apoptosis. Mol Med Rep. 2021 Feb;23(2):133. [Content Brief]

[7]. Hara H, et al. The NLRP6 Inflammasome Recognizes Lipoteichoic Acid and Regulates Gram-Positive Pathogen Infection. Cell. 2018 Nov 29;175(6):1651-1664.e14. [Content Brief]